# Nasal Protollin in Early Symptomatic Alzheimer's Disease

> **NCT07187141** · PHASE1 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 16 (actual)

## Conditions studied

- Alzheimer Disease (AD)

## Interventions

- **DRUG:** Protollin

## Key facts

- **NCT ID:** NCT07187141
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-18
- **Primary completion:** 2022-09-22
- **Final completion:** 2023-02-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187141, "Nasal Protollin in Early Symptomatic Alzheimer's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07187141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*